A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Back to Search
Print
Bookmark Trial

NCT00716859

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Pembroke Pines, Florida, 33028, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
36 + weeks
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female of 18 years of age or under

- Diagnosis of glaucoma

- IOP of 22 mmHg or above in at least 1 eye

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Require surgery for acute angle closure


- Have had prior cyclodestructive procedures


- Have a history of ocular trauma or surgery in either eye within 3 months of the
baseline visit

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

GlaucomaA Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma. NCT00716859
  1. Pembroke Pines, Florida
  2. Atlanta, Georgia
  3. Indianapolis, Indiana
  4. Minneapolis, Minnesota
  5. Henderson, Nevada
  6. Henderson, Nevada
  7. Las Vegas, Nevada
  8. Leuven,
  9. Medellín, Antioquia
  10. Bogota, Cundinamarca
  11. Praha 5,
  12. Amiens, Cedex 1
  13. Lille Cedex,
  14. Lyon,
  15. Regenstauf,
  16. Schorndorf,
  17. Hyderabad, Andhra Pradesh
  18. Ahmedabad, Gujarat
  19. Coimbatore, Tamilnadu
  20. Catania,
  21. Milano,
  22. Makati City,
  23. Mandaluyong City,
  24. Bialystok,
  25. Gdansk,
  26. Wroclaw,
  27. Coimbra,
  28. Lisboa,
  29. Lisboa,
  30. Lisboa,
  31. Porto,
  32. Cluj-Napoca, Cluj
  33. Moscow,
  34. St. Petersburg,
  35. Belgrade,
  36. Bratislava,
  37. Ljubljana,
  38. Myfair West,
  39. Esplugues de Llobregat, Barcelona
  40. Madrid,
  41. Sevilla,
  42. Kharkiv,
  43. Kyiv,
  44. Kyiv,
  45. Kyiv,
  46. Odesa,
  47. Birmingham,
  48. London,
ALL GENDERS
36 Weeks+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Official Title  ICMJE A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
Brief Summary To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Glaucoma
Intervention  ICMJE
  • Drug: Timolol
    Timolol 0.5% dosed twice-daily
  • Drug: latanoprost
    Latanoprost 0.005% ophthalmic solution dosed once-daily
Study Arms  ICMJE
  • Active Comparator: Timolol
    Intervention: Drug: Timolol
  • Experimental: latanoprost
    Intervention: Drug: latanoprost
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 5, 2010)		139
Original Estimated Enrollment  ICMJE
 (submitted: July 14, 2008)		120
Actual Study Completion Date  ICMJE November 2009
Actual Primary Completion Date November 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female of 18 years of age or under
  • Diagnosis of glaucoma
  • IOP of 22 mmHg or above in at least 1 eye

Exclusion Criteria:

  • Require surgery for acute angle closure
  • Have had prior cyclodestructive procedures
  • Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 36 Weeks to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Colombia,   Czech Republic,   France,   Germany,   India,   Italy,   Philippines,   Poland,   Portugal,   Romania,   Russian Federation,   Serbia,   Slovakia,   Slovenia,   South Africa,   Spain,   Ukraine,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00716859
Other Study ID Numbers  ICMJE A6111137
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP